GENOPLAN INC.

NEW YORK, NY · Founded 2015 · CIK 0001669736 · Biotech · Private

Genetic testing platform with interpretation and actionable health insights

genoplan.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$4.2M
1 Form D · Mar 2016
127 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$4,200,007
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2342Avm Biotechnology, LLC—$5.8M
2343INFIXION BIOSCIENCE, INC.——
2344BioLeap, Inc.—$5.0M
2345GENOPLAN INC.—$4.2M
2346LifeMine Therapeutics—$30M
2347MEDICON, INC.——
2348THYMMUNE THERAPEUTICS INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • Byungkyu KangDirector · Executive Officer · Promoter

Patents

USPTO · 0 granted of 2
  • Device And Method For Predicting Risk Of Disease Incidenceapplication
  • Method And Device For Training Model For Estimating Polygenic Risk Scoreapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.